Navigation Links
Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/11/2009

SAN DIEGO, Sept. 11 /PRNewswire/ -- Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009. The presentations will include comprehensive in vitro, in vivo, and clinical data on Calixa's anti-pseudomonal cephalosporin, CXA-101, alone and in combination with the beta-lactamase inhibitor, tazobactam.

CXA-101 is a potent, intravenously administered, anti-pseudomonal cephalosporin currently in Phase 2 study for the treatment of complicated urinary tract infections. Calixa recently initiated a Phase 1 study in healthy subjects for a second product, CXA-101/tazobactam. Tazobactam is a well established beta-lactamase inhibitor that could further enhance the excellent antibacterial activity of CXA-101 and potentially increase its clinical utility.

"This is an outstanding achievement for Calixa," said James Ge, M.D., Ph.D., chief scientific officer and executive vice president, of Calixa. "The 20 presentations give us a very strong presence at this major infectious disease conference, and reflect significant progress over the past year. We are particularly enthusiastic about the excellent clinical safety and pharmacokinetics profile CXA-101 exhibited in the Phase 1 studies conducted to date. We look forward to moving this promising compound, alone and in combination with tazobactam, to the next stages of clinical development."

The 20 presentations (F1-1985 to F1- 2004) relating to Calixa's antibiotic compounds will be presented in the Poster Session, Investigational Cephalosporins (Tuesday, September 15, 2009, 9:00 to 11:00 AM PDT). The title
'/>"/>

SOURCE Calixa Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...e-FirstCall/-- CryoLife,Inc. (NYSE: CRY ),animplan...eprocessingcompany,announcedtodaythatitisscheduled...althCareConferenceatTheNewYorkPalaceHotelonDecembe...xecutiveofficerofCryoLife,Inc.,willprovideacorpora...dhostaquestionandanswersessionat4:30p.m.EasternTim...
(Date:11/23/2009)...RNewswire-FirstCall/--WoundManagementTechnologies,...rofspecialtymedicalproducts,announcedthatithasfile...ivemanagementbusinessupdatetoillustratethedevelopm...ncreased33.5%to$102,926vs.Q32008salesof$77,084. ,...27,892vs.Q32008shareholderequityof$(321,257) ,...
(Date:11/23/2009)...Newswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ...partnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcont...goingphase2btrialofRG7128,afirst-in-classnucleosid...hepatitisCvirus(HCV)infection.Thedecisionwasreache...gCommittee(DMC)ofallavailablesafetydatafromthefirs...
Breaking Medicine Technology:CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 1Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 5Cerebrospinal fluid shows Alzheimers disease deterioration much earlier 49359 1Cerebrospinal fluid shows Alzheimers disease deterioration much earlier 49359 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 1Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 3Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 4
...ment in disease activity through three years...ease in adverse events, malignancies, infections o...ver time -, ROCKVILLE, Md., June 12 Human Genome...he presentation of results,from a long- term Phase...,(belimumab) was associated with sustained improve...
...e-FirstCall/ --,Pharmaceutical company Pharmaxis (...2 month Phase III clinical trial evaluating the sa...asis has completed., This 12-month treatment peri...fficacy trial which has already reported, showing ... clearance. The objective of the open,label extens...
Other Medicine Technology:Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 7Pharmaxis Long-Term Safety Study of Bronchitol Completes 2
(Date:11/24/2009)... Slate and New Markets build on their combined str.... , Baltimore, Md. (PRWEB...latecap.com ), a private equity firm based in Balt...( www.newmarketsvp.com ), a venture capital firm b...at they have acquired Ecoast Sales Solutions, Ltd....
(Date:11/24/2009)... Sinusitis patients life is regularly impacted by ...cs non-invasive nasal sinus treatment with Nasal n...pes of Sinusitis without any limitation or interfe...rs found 82.9% of patients treated with Sinus Dyna...particle diameter of 3.2 µm had a “goo...
(Date:11/24/2009).../PRNewswire-USNewswire/--Newpeer-revieweddatafindi...nsinfectedwithchronichepatitisCvirushavereceivedan...atCongressneedstomoveurgentlyonbipartisanlegislati...veillanceefforts,the NationalViralHepatitisRoundta...congressionalaction,millionsofAmericansinfectedwit...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)... After suffering from women,s hair loss for almost... and she,s sharing her progress and the secret beh...ugh the release of her video diaries which include... her treatment. , (PRWeb ...ferer Zsanett Siklosi has released the video diari...
Breaking Medicine News(10 mins):Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 4Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3
... read in its,entirety, "Why Do Drugs Cost So Much?...rHouse -- http://www.authorhouse.com ) may cause ...lief and even amusement., Written by the husband ... why are we so darn sick?" is not just,another bor...
...e/ -- Xinyu Hengdeli Holdings,Limited ("Xinyu Heng...Group"; HKEx: 3389), a leading enterprise engaged ...ernational watch brands in China, announced the,gr...Xinyu Elegant, the Group,s retail arm of high-end ...
...- A study presented at Digestive Disease Week 200...R) CT colonography guidelines recommending that po...onography by applying them to an endoscopic databa...to 9 mm in size and no larger polyps can have repe...
...linois hospital in six clinical,areas, CHICAGO, J... 10 clinical specialties -- six of which make it t...ews & World Report,s 2008,America,s Best Hospitals...ed according to the Top 50 programs,in 16 clinical...
...OD, Calif., July 10 Gov. Arnold Schwarzenegger,En...Lisa Paulsen, MPAA,Chair and CEO Dan Glickman, and...she will announce a major Hollywood anti-smoking i...IF brought,together Paramount Pictures, Sony Pictu...
...e overwhelming, bipartisan,approval to legislation...es--the best outcome possible given the difficult ...CP, president of the American,College of Physician...are more than enough to override a,presidential ve...
Other Medicine News:Health News:'Why Do Drugs Cost So Much? and why are we so darn sick?': New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health 2Health News:Grand Opening of Xinyu Elegant's Vacheron Constantin Boutique 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 3Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 4Health News:Northwestern Memorial Among America's Best Hospitals in 10 Clinical Specialties According to U.S. News' 2008 Rankings 2Health News:Northwestern Memorial Among America's Best Hospitals in 10 Clinical Specialties According to U.S. News' 2008 Rankings 3Health News:ACP applauds Senate to vote to pass H.R. 6331 and avert physician payment cut 2
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
Medicine Products: